Introduction
============

Lung cancer is one of the most commonly diagnosed tumors and continually leads to many deaths worldwide.[@b1-ott-9-6083] There were an estimated 1.8 million new cases of lung cancer in 2012, which occurred in the developing countries, accounting for 58% of the total cases. An estimated 1,987,909 new cases of lung cancer were diagnosed and 1,732,185 deaths were due to lung cancer in 2012. Moreover, lung cancer is the most common tumor in males.[@b2-ott-9-6083] The incidence of lung cancer is still obviously increasing.[@b3-ott-9-6083] The 5-year survival rate for lung cancer patients was only 16% in the past four decades, and the main obstacle in improving lung cancer prognosis was delayed diagnosis.[@b4-ott-9-6083] There are many reasons for the occurrence of lung cancer, but the major external risk factor was easily identified -- cigarette smoking. It has been reported that current smokers are approximately 20 times more likely than never smokers to develop lung cancer.[@b5-ott-9-6083],[@b6-ott-9-6083] Thus, smoking cessation is very important for public health. In addition, early detection and diagnosis play a crucial role in decreasing the mortality of lung cancer. Survival of lung cancer patients undergoing lung resection was more than 80%, which suggested that early detection and diagnosis helped immensely in the early treatment of lung cancer.[@b7-ott-9-6083],[@b8-ott-9-6083] Increasing evidence has indicated that polymorphisms of numerous susceptible genes play a significant association in the development of lung cancer. Thus, these polymorphisms could be useful as biomarkers for lung cancer detection.

Interleukin-10 (IL-10) cytokine, which is essential for T~H~2 responses, plays a central role in anti-inflammation and is also capable of blocking tumor immune surveillance to inhibit T-cell immunity.[@b9-ott-9-6083] A recent study has shown that the expression of IL-10 was associated with progression of tumors including lung cancer.[@b10-ott-9-6083] Some genetic polymorphisms of IL-10 gene, especially in the promoter region, could affect the expression of gene-encoded proteins associated with lung cancer susceptibility and prognosis.[@b11-ott-9-6083] Three SNPs at positions -1082, -592, and -819 of IL-10 gene promoter have been reported to be associated with expression of IL-10 gene.[@b12-ott-9-6083] Moreover, many individual studies have investigated the role of *IL-10 -1082A/G, -592C/A*, and -*819T/C* polymorphisms in lung cancer risk. Nevertheless, the results of these studies remained ambiguous and inconclusive owing to the reduced power of single studies. In this study, an updated meta-analysis was performed to estimate the effect of *IL-10 -1082A/G, -592C/A*, and -*819T/C* polymorphisms on lung cancer risk.

Material and methods
====================

Literature search strategy
--------------------------

The databases of PubMed, Embase, Web of Science, China National Knowledge Infrastructure, WanFang, and Database of Chinese Scientific and Technical Periodicals (VIP) were searched up to July 2016 to identify relevant studies published concerning the correlation of *IL-10 -1082A/G, -592 C/A*, and -*819T/C* polymorphisms with lung cancer risk. The following MESH terms and their synonyms were used: ("Lung Neoplasms" \[MESH\] or "lung cancer" or "lung tumor" or "lung carcinoma") and ("Interleukin-10" or "IL-10"). Language restriction was not applied in the process of retrieval. The reference lists of retrieved article were hand searched.

Inclusion criteria and exclusion criteria
-----------------------------------------

The following inclusion criteria were used: 1) studies investigating the association between *IL-10 -1082A/G, -592C/A*, and -*819T/C* polymorphisms and lung cancer risk; 2) studies with a case--control or cohort design; 3) studies with sufficient genotyping data available for calculation of odds ratios (ORs) and 95% confidence intervals (95% CIs); and 4) studies performed in humans. The exclusion criteria were as follows: 1) not a case--control or cohort study, 2) studies without available genotype data, 3) studies with duplicate data, and 4) meta-analysis and reviews.

Quality score assessment
------------------------

The Newcastle--Ottawa scale was used to assess the quality of studies included. Two investigators independently calculated the score of each study. The scores ranged from 0 to 9, and a score of ≥7 indicated a high quality study.

Data extraction
---------------

Two investigators independently searched articles and extracted the original data according to the inclusion criteria and exclusion criteria. The extracted information from each eligible study included the following: 1) the first author's name, 2) year of publication, 3) ethnicity, 4) source of controls, 5) number of cases and controls, and 6) genotype frequencies. Disagreement in data extraction was settled by consulting with the third investigator.

Statistical analysis
--------------------

The strength of association between *IL-10 -1082A/G, -592C/A*, and -*819T/C* polymorphisms and lung cancer risk was evaluated by calculating crude ORs and 95% CIs under an allele, a homozygous, a dominant, and a recessive model, respectively. Chi-square-based *Q*-test and *I*^2^ statistic test were performed to evaluate the heterogeneity assumption. A random-effects model (the DerSimonian and Laird method) was used to calculate the crude ORs of each study in case of *P*\<0.05 or *I*^2^\>50%, whereas a fixed-effects model (the Mantel--Haenszel method) was used if heterogeneity did not exist.[@b13-ott-9-6083],[@b14-ott-9-6083] Potential publication bias was evaluated using Begg's funnel plots and Egger's test. Sensitivity analysis was conducted to estimate the stability of the results by omitting each single study. The overall analysis and stratified analysis were performed using Stata 12.0 software (Stata Corp LP, College Station, TX, USA).

Results
=======

Characteristics of published studies
------------------------------------

Based on the inclusion criteria, a total of 372 publications were obtained on literature searching. After removing the articles that did not deal with the association of IL-10 polymorphism with lung cancer risk, reviews, and meta-analysis, 14 were left for further analysis. After further evaluation by reading full texts, four publications were excluded because of insufficient data on IL-10 genotype. Finally, 10 articles with 19 studies that investigated the correlation of *IL-10 -1082A/G, -592C/A*, and -*819T/C* polymorphisms with lung cancer risk were used for the further statistical analysis. Of these, eleven studies were conducted in Asians and eight studies were performed in Caucasians. In addition, eight publications were in English and two publications were in Chinese. The characteristics of all the studies included are listed in [Table 1](#t1-ott-9-6083){ref-type="table"} and shown in [Figure 1](#f1-ott-9-6083){ref-type="fig"}.

Quantitative analysis
---------------------

A total of 10 publications amounting to 19 case--control studies were included in this meta-analysis. In the overall analysis, the presence of *IL-10 -1082A/G* polymorphisms was associated with increased lung cancer risk, while *IL-10 -592C/A* polymorphisms were shown to decrease the lung cancer risk (for A-1082G, A vs G, OR =1.17, CI =1.04--1.30, *P*\<0.05; AA vs \[AG + GG\], OR =1.21, CI =1.05--1.40, *P*\<0.05; for C-592A, C vs A, OR =0.84, CI =0.77--0.91, *P*\<0.05; CC vs AA, OR =0.74, CI =0.64--087, *P*\<0.05; CC vs \[CA + AA\], OR =0.83, CI =0.74--0.94, *P*\<0.05; \[CC + CA\] vs AA, OR =0.79, CI =0.69--0.91, *P*\<0.05). When stratified by ethnicity, *IL-10 -1082A/G, C-592A*, and *T-819C* polymorphisms were associated with increased lung cancer risk in Asians (for -1082A/G, AA vs \[AG + GG\]: OR =1.20, CI =1.05--1.39, *P*\<0.05; for C-592A, C vs A, OR =1.36, CI =1.20--1.53, *P*\<0.05; CC vs AA, OR =1.85, CI =1.45--2.37, *P*\<0.05; CC vs \[CA + AA\], OR =1.36, CI =1.15--1.61, *P*\<0.05; for -*819T/C*, T vs C: OR =1.21, CI =1.06--1.38, *P*\<0.05; TT vs CC, OR =1.54, CI =1.18--2.01, *P*\<0.05; \[TT + TC\] vs CC, OR =1.51, CI =1.17--1.95, *P*\<0.05). Furthermore, when stratified based on disease type, a significant correlation was detected between *IL-10 T-819C* polymorphism and non-small-cell lung cancer (NSCLC; for -*819T/C*, T vs C: OR =1.57, CI =1.15--2.16, *P*\<0.05; TT vs CC, OR =3.15, CI =1.58--6.30, *P*\<0.05; \[TT + TC\] vs CC, OR =3.07, CI =1.58--5.93, *P*\<0.05). Interestingly, no significant association between *IL-10 -1082A/G, C-592A*, and *T-819C* polymorphisms and lung cancer risk was found in Caucasians. Furthermore, significantly decreased risk of lung cancer risk was found in the overall analysis of C-592A polymorphism, whereas significantly increased risk was detected in the Asian population ([Table 2](#t2-ott-9-6083){ref-type="table"}).

Heterogeneity analysis
----------------------

Under the homozygous genetic models, significant heterogeneity existed among the studies on *IL-10 -1082A/G* and -*819T/C* polymorphisms (for 1082A/G, *I*^2^=71.8%, *P*=0.007; for -*819T/C*, *I*^2^=88.0%, *P*=0.000). The forest plots suggested that ethnicity and disease type might be one of the sources of heterogeneity for *IL-10 -1082A/G* and -*819T/C* polymorphisms. However, heterogeneity was significantly lowered after the subgroup analyses based on ethnicity and disease type were conducted. This indicated that the ethnicity and disease type might lead to the heterogeneity. Furthermore, a meta-regression revealed that score, sample size, and genotyping method were not the sources of heterogeneity (for *IL-10 -1082A/G* and -*819T/C*, *P*\>0.05; [Figures 2](#f2-ott-9-6083){ref-type="fig"}[](#f3-ott-9-6083){ref-type="fig"}--[4](#f4-ott-9-6083){ref-type="fig"}).

Publication bias and sensitivity analysis
-----------------------------------------

On the basis of the Begg's test and Egger's test, no publication bias was found for the association between *IL-10 -1082A/G, -592C/A*, and -*819T/C* polymorphisms and lung cancer risk. Moreover, sensitivity analysis indicated that the results were stable after sequentially omitting each study ([Figures 5](#f5-ott-9-6083){ref-type="fig"}[](#f6-ott-9-6083){ref-type="fig"}--[7](#f7-ott-9-6083){ref-type="fig"}).

Discussion
==========

IL-10 was shown to have a significant effect on the tumorigenesis of different cancers and could even protect tumors by inhibiting the function of macrophages and dendritic cells, which present tumor cell antigens to the cytotoxic T lymphocytes.[@b15-ott-9-6083] Previous studies have found an association between IL-10 polymorphism and oral cancer, breast cancer, gastric cancer, colorectal cancer, esophageal cancer, hepatocellular cancer, cervical cancer, thyroid cancer, and nasopharyngeal cancer.[@b16-ott-9-6083]--[@b24-ott-9-6083] As for lung cancer, many studies have revealed that the loss of IL-10 expression could promote progression and poor clinical outcomes of lung cancer; however, the opposite effects were also found in some patients.[@b25-ott-9-6083] Interestingly, the absence of IL-10 had opposite effects on the early and late stages of NSCLC.[@b26-ott-9-6083] Hence, the expression or polymorphisms of IL-10 gene might serve as a good indicator of susceptibility and prognostic outcome for lung cancer in different stages of the disease.[@b27-ott-9-6083] These lung cancer biomarkers might be used for screening, early detection, early diagnosis, prognosis, prediction, stratification, and therapy response monitoring.[@b3-ott-9-6083] Although previous case--control studies showed that the IL-10 polymorphism might contribute to the risk of lung cancer, and the sample size of the studies was too small. Thus, this meta-analysis was performed.

Through this comprehensive meta-analysis, the association between *IL-10 -1082A/G, -592C/A*, and -*819T/C* polymorphism and the risk of lung cancer was evaluated. To our knowledge, this is the first systematic meta-analysis to date that deals with the association between *IL-10 -1082A/G, -592C/A*, and -*819T/C* polymorphisms and lung cancer risk. In the overall analysis, we found that *IL-10 -1082A/G, -592C/A*, and -*819T/C* polymorphisms were significantly associated with lung cancer risk. Interestingly, *IL-10 -1082A/G, -592C/A*, and -*819T/C* polymorphisms were significantly associated with lung cancer risk in Asians, but not in the Caucasians. Furthermore, the results indicated that individuals who carried the *IL-10 -1082G* allele had an increased risk of lung cancer, and those with the *IL-10 -819T* allele were shown to have a decreased risk of lung cancer compared to those with the -819C allele. The results of previous case--control studies by Shih et al,[@b28-ott-9-6083] Seifart et al,[@b29-ott-9-6083] Colakogullari et al,[@b30-ott-9-6083] and Peddireddy et al[@b31-ott-9-6083] for *IL-10 -1082A/G* polymorphism were consistent with this meta-analysis and indicated that the *IL-10 -1082A/G* polymorphism could increase the risk of lung cancer. The results of Hsia et al,[@b32-ott-9-6083] Shih et al,[@b28-ott-9-6083] and Zhang et al[@b33-ott-9-6083] for *IL-10 -819T/C* polymorphism showed that *IL-10 -819T/C* polymorphism was significantly associated with an increased risk of lung cancer. Nevertheless, different results were also found in the studies of Hsia et al[@b32-ott-9-6083] and Hart et al[@b34-ott-9-6083] concerning the *IL-10 -1082A/G* polymorphism. However, several of the included studies showed no significant correlation of *IL-10 A-592C* and -*819T/C* polymorphisms with lung cancer risk.[@b29-ott-9-6083],[@b30-ott-9-6083],[@b32-ott-9-6083],[@b34-ott-9-6083]--[@b36-ott-9-6083] In addition, there was adequate evidence indicating the different frequency distribution of *IL-10 -592C/A* and -*819T/C* allele between Asians and Caucasians in the meta-analysis. And this result was consistent with the data given in the HapMap database. Thus, a decreased risk of lung cancer in Caucasians and an increased risk of lung cancer in Asians was associated with the *IL-10 -592C/A* and -*819T/C* polymorphisms, although no significant association of *IL-10 -592C/A* and -*819T/C* polymorphisms with lung cancer risk in Caucasians was found. In addition, based on the results of the subgroup analysis, we found that *IL-10 -819T/C* polymorphism was associated with susceptibility to NSCLC. A previous study reported that IL-10 might be involved in the process of tumor escape from the immune response, and increased production of IL-10 has been shown to correlate with the survival of NSCLC patients.[@b28-ott-9-6083] However, only one study was included in the subgroup analysis, and this lowered the statistical power. For the *IL-10 -1082A/G* and -*592C/A* polymorphism, no significant correlation with NSCLC risk was detected. The analysis of small-cell lung cancer was not performed because the sample of small-cell lung cancer was too small and the classification of small-cell lung cancer was not clear. On the basis of the meta-analysis, to a large extent, there was no significant association between *IL-10 -1082A/G*, -*592C/A* polymorphism and NSCLC risk. To confirm this conclusion, studies with larger sample number must be conducted. The study results showed that subgroup analysis is very important for a systematic review and meta-analysis. From the studies included, there is evidence that the association between IL-10 polymorphism and lung cancer risk is still not clear. Therefore, performing a meta-analysis and systematic review was necessary to clarify this relevance. These results are shown in [Figure 3](#f3-ott-9-6083){ref-type="fig"}.

Limitations
===========

Several limitations of this meta-analysis should be acknowledged. First, the small number of eligible studies might limit the meta-analysis. There were only five or seven studies available for three SNPs of IL-10 gene in the stratification analysis in particular, which might have attenuated the statistical power of the meta-analysis. Second, the missing individual data, for example, cancer stage and cancer subtype might also have an impact on the interpretation. Third, this meta-analysis could not address the gene--environmental interactions in the correlation of IL-10 polymorphism with lung cancer risk. The conclusions only depend on the ORs, which might lead to confounding bias. Finally, the inclusion of data that was inconsistent with HWE might affect the accuracy of the results. However, the large sample size could weaken the impact of the association of IL-10 polymorphism with lung cancer risk.

In conclusion, this meta-analysis of ten case--control studies suggested that the *IL-10 -1082A/G, -592C/A*, and -*819T/C* polymorphisms were associated with the increased risk of lung cancer in Asians. Nevertheless, considering the limitations of the study, further large-scale, well-designed, and population-based studies are still needed to assess the correlation between IL-10 polymorphism and lung cancer risk.
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###### 

Characteristics of eligible studies included

  Author                                 Year   Controltype   Nationality                  Ethnicity    Disease          Control                                Case                                   *P* for HWE   Score   Genotyping method
  -------------------------------------- ------ ------------- ---------------------------- ------------ ---------------- ----------- -------- -------- -------- ----------- -------- -------- -------- ------------- ------- -------------------
  **A-1082G**                                                                                                            **Total**   **AA**   **AG**   **GG**   **Total**   **AA**   **AG**   **GG**                         
  Peddireddy et al[@b31-ott-9-6083]      2016   HB            India                        Asians       NSCLC            250         130      84       36       246         156      69       21       \<0.05        7       PCR-RFLP
  Hsia et al[@b32-ott-9-6083]            2014   HB            People's Republic of China   Asians       Lung neoplasms   716         561      130      25       358         273      69       16       \<0.05        7       PCR-RFLP
  Hart et al[@b34-ott-9-6083]            2011   HB            Norway                       Caucasians   NSCLC            435         104      226      105      436         120      207      109      0.41          7       TaqMan
  Hao et al[@b37-ott-9-6083]             2009   HB            People's Republic of China   Asians       Lung neoplasms   52          46       6                 44          36       7                 0.99          8       TaqMan
  Colakogullari et al[@b30-ott-9-6083]   2007   HB            Turkey                       Caucasians   Lung neoplasms   59          33       21       5        44          11       30       3        0.53          7       PCR-SSP
  Shih et al[@b28-ott-9-6083]            2005   HB            People's Republic of China   Asians       NSCLC            205         194      11       0        154         115      39       0        0.69          8       PCR-RFLP
  Seifart et al[@b29-ott-9-6083]         2005   HB            Germany                      Caucasians   Lung neoplasms   243         86       115      42       39          6        21       12       0.74          7       PCR-RFLP
  **A-592C**                                                                                                             **Total**   **CC**   **CA**   **AA**   **Total**   **CC**   **CA**   **AA**                         
  Zhang et al[@b33-ott-9-6083]           2015   HB            People's Republic of China   Asians       Lung neoplasms   336         75       176      85       330         110      156      64       0.37          7       PCR-RFLP
  Hsia et al[@b32-ott-9-6083]            2014   HB            People's Republic of China   Asians       Lung neoplasms   716         71       277      368      358         40       145      173      0.08          7       PCR-RFLP
  Hart et al[@b34-ott-9-6083]            2011   HB            Norway                       Caucasians   NSCLC            433         243      175      15       434         264      144      26       \<0.05        7       TaqMan
  Liang et al[@b35-ott-9-6083]           2011   HB            People's Republic of China   Asians       NSCLC            120         7        44       69       116         11       36       69       0.99          8       PCR-RFLP
  Vogel et al[@b36-ott-9-6083]           2008   PB            Denmark                      Caucasians   NSCLC            744         452      250      42       403         241      149      13       0.34          8       PCR-RFLP
  Colakogullari et al[@b30-ott-9-6083]   2007   HB            Turkey                       Caucasians   Lung neoplasms   59          27       25       7        44          19       23       2        0.74          7       PCR-SSP
  Shih et al[@b28-ott-9-6083]            2005   HB            People's Republic of China   Asians       NSCLC            205         13       76       116      154         18       70       66       0.91          8       PCR-RFLP
  **T-819C**                                                                                                             **Total**   **TT**   **TC**   **CC**   **Total**   **TT**   **TC**   **CC**                         
  Zhang et al[@b33-ott-9-6083]           2015   HB            People's Republic of China   Asians       Lung neoplasms   336         145      144      47       330         108      135      87       0.25          7       PCR-RFLP
  Hsia et al[@b32-ott-9-6083]            2014   HB            People's Republic of China   Asians       Lung neoplasms   716         372      265      79       358         212      128      18       \<0.05        7       PCR-RFLP
  Colakogullari et al[@b30-ott-9-6083]   2007   HB            Turkey                       Caucasians   Lung neoplasms   59          7        26       26       44          2        23       19       0.9           7       PCR-SSP
  Shih et al[@b28-ott-9-6083]            2005   HB            People's Republic of China   Asians       NSCLC            205         104      86       15       154         66       58       30       0.63          8       PCR-RFLP
  Seifart et al[@b29-ott-9-6083]         2005   HB            Germany                      Caucasians   Lung neoplasms   242         14       88       140      40          2        14       24       0.97          7       PCR-RFLP

**Abbreviations:** HB, control hospital based; PB, control population based; NSCLC, non-small-cell lung cancer; PCR, polymerase chain reaction; RFLP, restricted fragment length polymorphism; SSP, sequence specific primer.

###### 

Meta-analysis results of the association between *IL-10 -1082A/G, -592C/A*, and -*819T/C* polymorphisms and lung cancer risk

  IL-10         Allele model        Homozygous model   Dominant model      Recessive model                                                                
  ------------- ------------------- ------------------ ------------------- ----------------- ------------------------- -------- ------------------------- --------
  **A-1082G**   **A vs G**                             **AA vs GG**                          **AA vs (AG** + **GG)**            **(AA** + **AG) vs GG**   
  Caucasians    1.37 (0.98--1.35)   0.08               1.33 (0.97--1.83)   0.08              1.21 (0.94--1.55)         0.14     1.21 (0.92--1.58)         0.17
  Asians        1.14 (0.96--1.36)   0.14               0.99 (0.65--1.51)   0.95              1.20 (1.05--1.39)         \<0.05   1.15 (0.92--1.43)         0.21
  NSCLC         1.02 (0.89--1.18)   0.75               1.01 (0.77--1.33)   0.95              1.05 (0.87--1.27)         0.58     0.98 (0.76--1.27)         0.87
  Total         1.17 (1.04--1.30)   \<0.05             1.23 (0.98--1.54)   0.07              1.21 (1.05--1.40)         \<0.05   1.15 (0.92--1.43)         0.21
  **C-592A**    **C vs A**                             **CC vs AA**                          **CC vs (CA** + **AA)**            **(CC** + **CA) vs AA**   
  Caucasians    0.96 (0.83--1.11)   0.55               0.88 (0.59--1.33)   0.55              0.96 (0.80--1.14)         0.62     0.89 (0.60--1.34)         0.58
  Asians        1.36 (1.20--1.53)   \<0.05             1.85 (1.45--2.37)   \<0.05            1.36 (1.15--1.61)         \<0.05   0.74 (0.62--0.87)         \<0.05
  NSCLC         0.98 (0.87--1.10)   0.70               0.96 (0.77--1.21)   0.74              0.98 (0.84--1.14)         0.75     0.97 (0.79--1.20)         0.79
  Total         0.84 (0.77--0.91)   \<0.05             0.74 (0.64--0.87)   \<0.05            0.83 (0.74--0.94)         \<0.05   0.79 (0.69--0.91)         \<0.05
  **T-819C**    **T vs C**                             **TT vs CC**                          **TT vs (TC** + **CC)**            **(TT** + **TC) vs CC**   
  Caucasians    0.96 (0.65--1.41)   0.82               1.36 (0.44--4.17)   0.59              1.50 (0.50--4.50)         0.47     0.85 (0.53--1.38)         0.52
  Asians        1.21 (1.06--1.38)   \<0.05             1.54 (1.18--2.01)   \<0.05            1.15 (0.97--1.37)         0.11     1.51 (1.17--1.95)         \<0.05
  NSCLC         1.57 (1.15--2.16)   \<0.05             3.15 (1.58--6.30)   \<0.05            1.37 (0.90--2.09)         0.14     3.07 (1.58--5.93)         \<0.05
  Total         0.97 (0.86--1.10)   0.63               0.95 (0.76--1.20)   0.68              0.96 (0.82--1.14)         0.66     0.97 (0.79--1.19)         0.77

**Abbreviations:** NSCLC, non-small-cell lung cancer; OR, odds ratio; 95% CI, 95% confidence interval.
